Anhui Anke Biotechnology (Group) Co., Ltd.

XSEC:300009 Stock Report

Market Cap: CN¥13.8b

Anhui Anke Biotechnology (Group) Past Earnings Performance

Past criteria checks 2/6

Anhui Anke Biotechnology (Group) has been growing earnings at an average annual rate of 27.9%, while the Biotechs industry saw earnings declining at 1.6% annually. Revenues have been growing at an average rate of 10.8% per year. Anhui Anke Biotechnology (Group)'s return on equity is 16.6%, and it has net margins of 27.8%.

Key information

27.9%

Earnings growth rate

27.3%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate10.8%
Return on equity16.6%
Net Margin27.8%
Last Earnings Update31 Mar 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Anhui Anke Biotechnology (Group) makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSEC:300009 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 252,509698984198
31 Dec 242,536707994201
30 Sep 242,7667831,091230
30 Jun 242,8778671,096235
31 Mar 242,9288791,083256
31 Dec 232,8668471,055255
30 Sep 232,646763954211
30 Jun 232,538755900207
31 Mar 232,392716861172
01 Jan 232,331703877166
30 Sep 222,328372862174
30 Jun 222,280307911168
31 Mar 222,217254941163
31 Dec 212,169207947167
30 Sep 212,096489944154
30 Jun 211,959441900134
31 Mar 211,871403867142
31 Dec 201,701359795129
30 Sep 201,702167781117
30 Jun 201,661140776119
31 Mar 201,681140785118
31 Dec 191,713124816120
30 Sep 191,607289799118
30 Jun 191,598280799112
31 Mar 191,52927078493
31 Dec 181,46226374487
30 Sep 181,38231765471
30 Jun 181,27629256499
31 Mar 181,17729050386
31 Dec 171,09627846570
30 Sep 171,00924945147
30 Jun 179412284660
31 Mar 178782094170
31 Dec 168491974020
30 Sep 167511693550
30 Jun 166961603180
31 Mar 166711483110
31 Dec 156361362980
30 Sep 156291372860
30 Jun 156091272840
31 Mar 155791152760
31 Dec 145421102570
30 Sep 145091072380
30 Jun 14472992210

Quality Earnings: 300009 has high quality earnings.

Growing Profit Margin: 300009's current net profit margins (27.8%) are lower than last year (30%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 300009's earnings have grown significantly by 27.9% per year over the past 5 years.

Accelerating Growth: 300009's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 300009 had negative earnings growth (-20.6%) over the past year, making it difficult to compare to the Biotechs industry average (-18.7%).

Return on Equity

High ROE: 300009's Return on Equity (16.6%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/07 00:00
End of Day Share Price 2025/05/07 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Anhui Anke Biotechnology (Group) Co., Ltd. is covered by 15 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shuchang LiuChangjiang Securities Co. LTD.
Pei Hui TangChasing Securities
Pei ChengChina Galaxy Securities Co., Ltd.